Dupilumab provides clinical benefit to adolescents with moderate-to-severe atopic dermatitis


Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab. The results from these latest studies, which are reported in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the medication for up to 52 weeks of treatment.

Dupilumab works by stopping the action of certain substances in the body that cause the symptoms of eczema. Specifically, it is a monoclonal antibody against interleukin-4 receptor alpha.

Adolescents with moderate-to-severe atopic dermatitis have a high disease burden that negatively affects quality of life, and patients are in need of therapies that can be used long-term. Results from these trials show that dupilumab provides substantial and sustained clinical benefit to these patients with an acceptable safety profile.”

Ashish Bansal, MD, senior author from Regeneron Pharmaceuticals, Inc., in Tarrytown, New York

Journal reference:

Cork, M.J, et al. (2019) Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology. doi.org/10.1111/bjd.18476.

Products You May Like

Articles You May Like

GlobalData reveals 21.7% drop in US medical devices industry deals during April 2020
Immunology – NOD like receptors and the Inflammasome
Research opens new horizons for studies on potentially health promoting foods
Flu and Acute Respiratory Distress Syndrome (ARDS) – Mayo Clinic
Study shows high prevalence of vaping in U.S. schools

Leave a Reply

Your email address will not be published. Required fields are marked *